阿柏西普在增殖型糖尿病视网膜病变患者中的应用效果
Application effect of aflibercept in patients with proliferative diabetic retinopathy
杨宏忠 1高淑娟1
作者信息
- 1. 铜川矿务局中心医院,陕西铜川,727000
- 折叠
摘要
目的 分析阿柏西普在增殖型糖尿病视网膜病变(PDR)患者中的应用效果.方法 选取2019年7月至2021年7月我院收治的80例PDR患者为研究对象,将其随机分为对照组(n=40,玻璃体切除术治疗)和研究组(n=40,阿柏西普+玻璃体切除术治疗).比较两组的治疗效果.结果 研究组的治疗总有效率为95.00％,高于对照组的77.50％(P＜0.05).治疗后,研究组的收缩期血流峰值流速(PSV)、舒张末期血流速度(EDV)高于对照组,阻力指数(RI)及血管内皮生长因子(VEGF)、促红细胞生成素(EPO)、血管生成素-2(Ang-2)、缺氧诱导因子-1α(HIF-1α)、miR-210水平低于对照组(P＜0.05).术后1周、1个月、3个月,研究组的最佳矫正视力高于对照组(P＜0.05).结论 阿柏西普+玻璃体切除术治疗PDR患者可取得理想疗效,能改善血流动力学、血清指标及提高术后视力,值得临床推广及应用.
Abstract
Objective To analyze the application effect of aflibercept in patients with proliferative diabetic retinopathy(PDR).Methods A total of 80 patients with PDR admitted in our hospital from July 2019 to July 2021 were selected as the objects and randomly divided into control group(n=40,treated with vitrectomy)and study group(n=40,treated with aflibercept+vitrectomy).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was 95.00％,which was higher than 77.50％in the control group(P＜0.05).After treatment,the peak systolic velocity(PSV)and end diastolic velocity(EDV)in the study group were higher than those in the control group,and the resistance index(RI)and the levels of vascular endothelial growth factor(VEGF),erythropoietin(EPO),angiopoietin-2(Ang-2),hypoxia inducible factor-1α(HIF-1α)and miR-210 were lower than those in the control group(P＜0.05).At 1 week,1 month and 3 months after operation,the best corrected visual acuity of the study group was higher than that of the control group(P＜0.05).Conclusion The aflibercept+vitrectomy can achive ideal results in the treatment of PDR patients,improve hemodynamics,serum indicators and enhance postoperative visual acuity.It is worthy of clinical promotion and application.
关键词
增殖型糖尿病视网膜病变/阿柏西普/血流动力学/视力Key words
proliferative diabetic retinopathy/aflibercept/hemodynamics/visual acuity引用本文复制引用
出版年
2024
NETL
NSTL
万方数据